Antiangiogenic Agents in the Treatment of HER2-Negative Metastatic breast Cancer: A Brief Review

Author(s): Nabil Ismaili.

Journal Name: Current Angiogenesis (Discontinued)

Volume 3 , Issue 2 , 2014

Graphical Abstract:


Abstract:

Angiogenesis is an important step in breast cancer (BC) growth and progression. Targeting angiogenesis was the most interesting by developed strategy in the treatment of HER2-negative BC. Bevacizumab is a monoclonal humanized antibody targeting the vascular endothelial growth factor (VEGF) the most potent factor implicated in tumor angiogenesis. It is the most developed targeted agent in HER2-negative MBC and showed the most interesting results in combination with chemotherapy. Currently, bevacizumab is the only approved targeted therapy (in Europe only) in the first line treatment of HER2-negative metastatic BC in combination with weekly paclitaxel. The aim of the present paper is to review the role of anti-angiogenic agents (targeted agents only) in the treatment of HER2-negative metastatic BC.

Keywords: Anti-angiogenic agents, bevacizumab, breast cancer, VEGF, VEGFR.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 2
Year: 2014
Page: [73 - 79]
Pages: 7
DOI: 10.2174/2211552803666141003221604
Price: $58

Article Metrics

PDF: 6